Trial Profile

Prospective Observational Post Marketing Surveillance Study to Observe Safety and Effectiveness of Zavicefta IV

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Avibactam/ceftazidime (Primary)
Indications Bacteraemia; Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
Focus Adverse reactions
Sponsors Pfizer

Most Recent Events

16 Apr 2024 Status changed from not yet recruiting to recruiting.
31 Jan 2024 Planned primary completion date changed from 1 Jan 2029 to 28 Sep 2029.
31 Jan 2024 Planned initiation date changed from 1 Dec 2023 to 31 Jan 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com